Order results by:
| Issue | Title | |
| Vol 15 (2023): (Suppl. 1) | The evolution of interferon therapy in multiple sclerosis | Abstract similar documents |
| O. V. Boyko, N. F. Smirnova, A. N. Boyko | ||
| "... The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis ..." | ||
| Vol 17, No 3 (2025) | Curcumin as add-on therapy in patients with multiple sclerosis showing a suboptimal response to first-line disease-modifying therapies: clinical outcomes and in vitro data | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaia, E. V. Lysogorskaia, A. N. Boyko | ||
| "... curcumin on clinical and immunological parameters in MS patients receiving interferon (IFN) therapy ..." | ||
| Vol 7, No 3 (2015) | Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis | Abstract similar documents |
| V. R. Mkrtchyan, L. V. Brylev, O. V. Davydova, A. V. Belyanin, I. A. Shpak, A. M. Sergeev | ||
| "... analyses were performed for intramuscular interferon (INF)-β1a (avonex, 30 μg), subcutaneous INF-β1a (rebif ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Review of human interferons and the potential of their use in the complex therapy of a new coronavirus infection COVID-19 | Abstract similar documents |
| E. V. Granatov, A. R. Abashev, F. A. Khabirov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... Interferons (IFNs) were first discovered over 60 years ago in a classic experiment by Isaacs ..." | ||
| Vol 16 (2024): (Suppl. 2) | Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy | Abstract similar documents |
| A. D. Kukushkina, V. S. Rogovskii, E. V. Ponevezhskaya, E. V. Lysogorskaia, A. N. Boyko | ||
| "... . Material and methods. MS patients (n=40) receiving interferon-β (IFNβ) therapy who showed a suboptimal ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a) | Abstract similar documents |
| A. N. Boyko | ||
| "... with interferon-β drugs due to pegylation is discussed. Without losing its effectiveness, sampeginterferon beta-1a ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Attitude to reproduced disease modifying therapies in patients with relapsing-remitting multiple sclerosis: results of a medical and sociological study | Abstract similar documents |
| Ya. V. Vlasov, M. V. Churakov, E. V. Sineok, A. N. Boyko | ||
| "... six regions of the Russian Federation, receiving interferon beta-1a 44 μg, interferon beta-1b ..." | ||
| Vol 15, No 3 (2023) | Inflammatory biomarkers and growth factors in patients with chronic cerebrovascular disease after coronavirus infection | Abstract similar documents |
| E. B. Kuznetsova, O. N. Voskresenskaya, N. B. Zakharova, N. S. Kuznetsov | ||
| "... in blood serum – tumor necrosis factor α (TNF α ), interleukin 6 (IL6), IL18, interferon γ (IFN γ ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... SinnoVex is a drug from the group of bioanalogues of interferon beta-1a for intramuscular ..." | ||
| Vol 16 (2024): (Suppl. 2) | Sampeginterferon beta-1a in clinical practice | Abstract similar documents |
| I. A. Sokolova, O. S. Kornakova, E. V. Sokolova | ||
| "... ) into clinical practice can improve treatment outcomes. Interferon beta drugs are commonly used as DMTs. Among ..." | ||
| Vol 11, No 1 (2019) | Anti-MOG syndrome: two case reports | Abstract PDF (Eng) similar documents |
| A. S. Kotov | ||
| "... occurred during interferon-β therapy. In the other case the syndrome also began with optic neuritis ..." | ||
| Vol 7, No 1 (2015) | Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use | Abstract similar documents |
| I. D. Stolyarov, A. M. Petrov, M. V. Votintseva, I. G. Nikiforova | ||
| "... development of medicine. Due to the fact that most of them belong to interferons-β, i.e. biologicals ..." | ||
| Vol 10, No 2 (2018) | Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. M. Lila, A. N. Gromov | ||
| "... the synthesis of IgA, the migration of leukocytes, and the activity of hematopoietin and interferon receptors ..." | ||
| Vol 14, No 2 (2022) | New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation. | Abstract similar documents |
| A. K. Minochkin, V. Yu. Lobzin, N. N. Suchentseva, O. S. Popov, S. V. Apalko, S. G. Sherbak | ||
| "... the concentration of growth/differentiation factor 15 and interferon γ in blood plasma and FAB scores in patients ..." | ||
| Vol 12, No 2 (2020) | Systematic analysis of the molecular pathophysiology of tenosynovitis: promise for using chondroitin sulfate and glucosamine sulfate | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. M. Lila, O. A. Limanova | ||
| "... of proinflammatory cytokines (IL-1, IL-8, γ-interferon, and TNF-α), monocyte chemoattractant protein-1 (MCP-1 ..." | ||
| Vol 9, No 1 (2017) | Clinical and epidemiological features of patients with multiple sclerosis in the Kursk Region | Abstract similar documents |
| V. B. Laskov, E. A. Logacheva, E. E. Tretyakova, M. A. Gridnev | ||
| "... and interferons were most frequently prescribed as DMDs for MS in the region. Conclusion. The findings may ..." | ||
| Online-first | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... with a four-year history of the disease showed resistance to first-line therapy (interferon β1a and glatiramer ..." | ||
| Vol 17, No 1 (2025) | The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series | Abstract similar documents |
| E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko | ||
| "... with a four-year history of the disease showed resistance to first-line therapy (interferon β1a and glatiramer ..." | ||
| Vol 16 (2024): (Suppl. 2) | Cytokine levels in patients with multiple sclerosis and chronic neuroborreliosis | Abstract similar documents |
| N. S. Baranova, L. A. Ovsyannikova, Ya. S. Ostapenko, N. N. Spirin, A. A. Baranov, M. S. Gris, A. S. Artyukhov, Yu. V. Manyakina | ||
| "... , IL17F, IL21, IL22, IL23, IL25, IL31, IL33, interferon γ (IFNγ), tumor necrosis factor α (TNFα ..." | ||
| 1 - 19 of 19 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
